Norpace Tablet
Disopyramide
150mg
RPG Life Sciences Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 15.78 NPR |
Available as:
Indications
Norpace Tablet is used for:
Ventricular tachycardia, Supraventricular and Ventricular arrhythmias
Adult Dose
Oral
Supraventricular and ventricular arrhythmias
Adult: 300-800 mg daily in divided doses (as conventional capsules every 6 hr), adjusted according to patient's response.
Hepatic impairment: 400 mg daily in divided doses. Liver cirrhosis: consider a therapeutic range 50% lower than in patients with normal hepatic function.
Child Dose
Oral
Ventricular Arrhythmias
<1 year old: 10-30 mg/kg/day divided q6hr PO
1-4 years old: 10-20 mg/kg/day divided q6hr PO
4-12 years old: 10-15 mg/kg/day divided q6hr PO
12-18 years old: 6-15 mg/kg/day divided q6hr PO
Renal Dose
Renal impairment:
CrCl (ml/min)
>40 400 mg daily in divided doses.
30-40 100 mg every 8 hr; avoid modified release preparations.
15-30 100 mg every 12 hr; avoid modified release preparations.
<15 100 mg every 24 hr; avoid modified release preparations.
Administration
Contra Indications
Patients with complete heart block; glaucoma; predisposition to urinary retention; myasthenia gravis. Sinus node disease in absence of pacemaker. Cardiomyopathy. Cardiogenic shock. Hypotension. Hypersensitivity. Children.
Precautions
Conduction disorders or uncompensated heart failure. Pregnancy and lactation. Renal and hepatic failure. Family history of glaucoma. Correct potassium deficiency.
Lactation: crosses into breast milk, discontinue drug or do not nurse
Pregnancy-Lactation
Interactions
Avoid other Class I antiarrhythmics and other cardiac depressants including beta-blockers except in life-threatening arrhythmias. Risk of worsening of arrhythmias, precipitation of new arrhythmias and ventricular fibrillation when used with other anti-arrhythmics. Reduced efficacy when co-admin with phenytoin.
Potentially Fatal: Enhanced antimuscarinic effects with other antimuscarinic drugs. Potentiates negative chronotropic and inotropic effects of ?-blockers and verapamil. Potentiates inhibitory effect on the conduction system produced by digitalis. Potentiates QT interval prolongation produced by TCAs and amiodarone.
Adverse Effects
Side effects of Disopyramide :
>10%
Xerostomia (32%),Urinary hesitancy (23%),Constipation (11%)
1-10%
Impotence,Urinary urgency,Urinary retention,Dry throat,Weight gain,Abdominal distension,Flatulence,Anorexia,Vomiting,Nausea,Dermatoses,Pruritus,Generalized rash,Increased triglycerides and cholesterol,Hypokalemia,Muscle weakness,Muscular pain,Dyspnea,Blurred vision,Dry eyes,Fatigue,Malaise,Headache,Dizziness,Nervousness,Syncope,Hypotension,Chest pain,Edema
<1%
AV block,Hypoglycemia (rare),Agranulocytosis,Respiratory distress,Creatinine increased,Psychotic reaction,Paresthesia,Lupus (rare),Peripheral neuropathy,Insomnia
Potentially Fatal: Urinary retention, severe cardiovascular depression if given as rapid IV inj. High risk of recurrence of failure in patients with history of congestive cardiac failure. Negative inotropic effect especially prominent in patients with cardiomyopathy, hypertension and uncompensated cardiac failure.
Mechanism of Action
Disopyramide is a Ia antiarrhythmic agent which acts by decreasing myocardial excitability and conduction velocity. It lengthens the effective refractory period of the atrium. It also possesses antimuscarinic and negative inotropic effects.
Note
Norpace 150mg Tablet manufactured by RPG Life Sciences Ltd.. Its generic name is Disopyramide. Norpace is availble in Nepal.
Farmaco Nepal drug index information on Norpace Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.